Medtronic is a star of the medical-device industry, leading the markets for pacemakers, implantable cardioverter defibrillators (ICDs), neurological devices and spinal products. And there's more where that came from -- its pipeline of new products is deep. But the company's stock looks like it suffered a coronary this year, dropping 14% since mid January.
The problem is Medicare. Cowen Co. analyst Dhulsini de Zoysa says Wall Street is worried that possible cuts in Medicare reimbursement rates, particularly for ICD therapy, could hurt Medtronic's profitability. The stock's recent decline makes it unusually cheap, and he suggests investors take advantage. The stock (MDT), recently $52, trades at just 18 times de Zoysa's calendar 2007 earnings estimate of $2.79 per share -- near its lowest valuation in ten years, he says.
De Zoysa thinks concerns over reimbursements are overblown. While rates could drop, he doesn't think drastic changes are likely. And besides, ICDs account for less than one-third of Medtronic's revenues. That means the company can withstand changes that could hurt less-diversified companies, such as St. Jude Medical (STJ), he says.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Medtronic is planning to launch a number of products to drive sales growth, including cardiac rhythm management products, artificial discs and a treatment for diabetes. Its hopes that its drug-eluding stent, which is already available in Europe, will be approved for use in the U.S. next year. De Zoysa expects Medtronic to continue spending heavily on research and development, about 10% of yearly revenues.
Analysts, on average, expect Medtronic to earn $2.52 per share in the fiscal year that ends April 2007, according to Thomson First Call.
--Lisa Dixon
-
The Most Tax-Friendly States for Investing in 2025 (Hint: There Are Two)State Taxes Living in one of these places could lower your 2025 investment taxes — especially if you invest in real estate.
-
Want To Retire at 55? See If You Can Answer These Five QuestionsWho said you can’t retire at 55? If you say yes to these questions, you may be on your way to an early retirement.
-
If You'd Put $1,000 Into Sherwin-Williams Stock 20 Years Ago, Here's What You'd Have TodaySherwin-Williams stock has clobbered the broader market by a wide margin for a long time.
-
If You'd Put $1,000 Into UnitedHealth Group Stock 20 Years Ago, Here's What You'd Have TodayUNH stock was a massive market beater for ages — until it wasn't.
-
What Tariffs Mean for Your Sector ExposureNew, higher and changing tariffs will ripple through the economy and into share prices for many quarters to come.
-
How to Invest for a Fall Interest Rate Cut by the FedA lot can happen between now and then, but the probability the Fed cuts interest rates in September is back above 80%.
-
Are Buffett and Berkshire About to Bail on Kraft Heinz Stock?Warren Buffett and Berkshire Hathaway own a lot of Kraft Heinz stock, so what happens when they decide to sell KHC?
-
How the Stock Market Performed in the First 6 Months of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Berkshire Hathaway Stock 20 Years Ago, Here's What You'd Have TodayBerkshire Hathaway is a long-time market beater, but the easy money in BRK.B has already been made.
-
If You'd Put $1,000 Into Procter & Gamble Stock 20 Years Ago, Here's What You'd Have TodayProcter & Gamble stock is a dependable dividend grower, but a disappointing long-term holding.
